1. Home
  2. ARVN vs CBLL Comparison

ARVN vs CBLL Comparison

Compare ARVN & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$10.47

Market Cap

781.0M

Sector

Health Care

ML Signal

HOLD

Logo CeriBell Inc.

CBLL

CeriBell Inc.

HOLD

Current Price

$19.03

Market Cap

750.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
CBLL
Founded
2015
2014
Country
United States
United States
Employees
N/A
280
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
781.0M
750.1M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ARVN
CBLL
Price
$10.47
$19.03
Analyst Decision
Buy
Strong Buy
Analyst Count
20
6
Target Price
$15.35
$24.67
AVG Volume (30 Days)
763.2K
297.5K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
$29.57
Revenue Next Year
N/A
$28.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.90
$10.01
52 Week High
$14.22
$24.33

Technical Indicators

Market Signals
Indicator
ARVN
CBLL
Relative Strength Index (RSI) 29.80 49.38
Support Level $9.02 $18.78
Resistance Level $14.03 $20.09
Average True Range (ATR) 0.69 0.70
MACD -0.32 0.15
Stochastic Oscillator 2.36 72.39

Price Performance

Historical Comparison
ARVN
CBLL

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

About CBLL CeriBell Inc.

CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

Share on Social Networks: